European Biotech Acquisition Corp. Class A Ordinary Shares
EBAC
EBAC was delisted on the 2nd of March, 2023.
50 hedge funds and large institutions have $86.9M invested in European Biotech Acquisition Corp. Class A Ordinary Shares in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
17% more capital invested
Capital invested by funds: $74.3M → $86.9M (+$12.6M)
9.94% more ownership
Funds ownership: 57.45% → 67.38% (+9.9%)
9% more funds holding
Funds holding: 46 → 50 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$4.89M |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$3.32M |
| 3 |
GCL
Glazer Capital LLC
New York
|
+$2.83M |
| 4 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
+$2.26M |
| 5 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$1.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
-$2.94M |
| 2 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
-$1.97K |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$197 |
| 4 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$10 |
EBAC Hedge Fund Activity: Q3 2022 in Review
50 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) for Q3 2022, worth a combined $86.9M — up 17% from $74.3M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new EBAC positions and 2 closed out — a net gain of 5 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was BNP Paribas Financial Markets, opening a new position worth an estimated $4.89M. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $2.94M sold.
- 50 institutional investors held European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) as of Q3 2022, up from 46 in Q2 2022.
- Funds reported $86.9M of European Biotech Acquisition Corp. Class A Ordinary Shares stock for Q3 2022, up 17% quarter-over-quarter.
- 7 funds opened new European Biotech Acquisition Corp. Class A Ordinary Shares positions in Q3 2022 and 2 closed out, a net change of +5 holders.
- The largest European Biotech Acquisition Corp. Class A Ordinary Shares buyer in Q3 2022 was BNP Paribas Financial Markets, an estimated $4.89M added.
- The largest European Biotech Acquisition Corp. Class A Ordinary Shares seller in Q3 2022 was Suvretta Capital Management, an estimated $2.94M sold.
Based on aggregated 13F filings for Q3 2022.